The emergency department (ED) nurse is caring for a patient who is experiencing pulmonary edema. The patient is treated with furosemide (Lasix). What will the nurse monitor?
A) Sodium levels
B) Bone narrow function
C) Calcium levels
D) Potassium levels
D
Feedback:
Furosemide is associated with loss of potassium, so that the patient will need to be monitored carefully for low potassium levels, which could cause cardiac arrhythmias and further aggravate pulmonary edema. The nurse would not monitor sodium or calcium levels or bone marrow function because of the effects of the drug during the acute treatment of pulmonary edema.
You might also like to view...
A patient states that she uses the Internet to look up everything related to her medical condition and treatment and so does not need the teaching prepared by the nurse
What aspects of health literacy are especially important for the nurse to assess in this patient? (Select all that apply.) a. Ability to condense a huge amount of information b. Ability to determine what information is reliable c. Motivation of the patient to do her own research d. Reason the patient prefers learning on the Internet e. Trust in the nurse to provide accurate information
On otoscopy, what middle ear mass is seen as a red blemish behind the tympanic membrane?
A) Acoustic tumor B) Choesteatoma C) Facial nerve neuroma D) Glomus tympanicum
One method for the nurse to assess if there is sufficient dietary fiber in a client's diet would be to:
1. Recommend the addition of refined flour products. 2. Avoid plant based proteins. 3. Closely monitor weight gain or loss. 4. Conduct a brief diet history of plant-based foods.
The nurse is providing education to a client who was taking sibutramine (Meridia) as a part of a weight-loss program. The client asks the nurse why the medication was removed from the market. Which statement by the nurse is most appropriate?
1. "Sibutramine (Meridia) was removed from the market due to the adverse effects of postnasal drainage, pruritus, and drowsiness." 2. "Sibutramine (Meridia) was removed from the market due to the adverse effects of headache, constipation, and xerostomia." 3. "Sibutramine (Meridia) was removed from the market to the increased risk of heart attack and stroke." 4. "Sibutramine (Meridia) was removed from the market due to the increased risk for facial twitching, backache, and anxiety."